The biology of miRNAs in B cell malignancies and their use as biomarkers

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00075109" target="_blank" >RIV/65269705:_____/21:00075109 - isvavai.cz</a>

Výsledek na webu

<a href="http://precisiondiagnostics.eu/programme/" target="_blank" >http://precisiondiagnostics.eu/programme/</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The biology of miRNAs in B cell malignancies and their use as biomarkers

Popis výsledku v původním jazyce

B Cell Receptor (BCR) signalling is fundamental for the maturation, survival, and proliferation of B cells, and B cell malignancies frequently harbour mutations in this pathway or complex nongenetic deregulation of BCR signalling. This pathway cross-talks with other essential pathways in the microenvironment of malignant B cells, especially B-T cell interactions and cell adhesion. This is underscored by the remarkable clinical effect of inhibitors targeting BCR-associated kinases BTK and PI3K, especially in chronic lymphocytic leukaemia (CLL). The differences in BCR signalling propensity contribute to variable prognosis in CLL and other &quot;mature&quot; B cell malignancies, and it has been shown that non-coding RNAs such as miR-150, miR-155, miR-34a or miR-17-92 play an important role in this process. The talk will focus on novel roles of microRNAs (miRNAs) in fine tuning the propensity of BCR signalling during microenvironmental interactions of B cells, and also the related changes during therapy with BCR inhibitors or classical DNA-damaging therapeutic drugs. This will include novel data on MYC-regulated and p53-regulated miRNAs acting as regulators of survival and proliferation of malignant B cells. The understanding of these miRNA functions allowed the development of several patented miRNA-based biomarkers that can be used to predict therapeutic response and/or overall survival in B cell malignancies such as chronic lymphocytic leukaemia and follicular lymphoma.

Název v anglickém jazyce

The biology of miRNAs in B cell malignancies and their use as biomarkers

Popis výsledku anglicky

B Cell Receptor (BCR) signalling is fundamental for the maturation, survival, and proliferation of B cells, and B cell malignancies frequently harbour mutations in this pathway or complex nongenetic deregulation of BCR signalling. This pathway cross-talks with other essential pathways in the microenvironment of malignant B cells, especially B-T cell interactions and cell adhesion. This is underscored by the remarkable clinical effect of inhibitors targeting BCR-associated kinases BTK and PI3K, especially in chronic lymphocytic leukaemia (CLL). The differences in BCR signalling propensity contribute to variable prognosis in CLL and other &quot;mature&quot; B cell malignancies, and it has been shown that non-coding RNAs such as miR-150, miR-155, miR-34a or miR-17-92 play an important role in this process. The talk will focus on novel roles of microRNAs (miRNAs) in fine tuning the propensity of BCR signalling during microenvironmental interactions of B cells, and also the related changes during therapy with BCR inhibitors or classical DNA-damaging therapeutic drugs. This will include novel data on MYC-regulated and p53-regulated miRNAs acting as regulators of survival and proliferation of malignant B cells. The understanding of these miRNA functions allowed the development of several patented miRNA-based biomarkers that can be used to predict therapeutic response and/or overall survival in B cell malignancies such as chronic lymphocytic leukaemia and follicular lymphoma.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10600 - Biological sciences

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů